Venture investor’s big move: Latigo Biotherapeutics (ALMS) lands new 14.5% holder
Foresite Capital funds and management, led by James B. Tananbaum, filed a Schedule 13D for Latigo Biotherapeutics (ALMS) common stock, reporting ownership changes after prior purchases of Series A-2 and Series B convertible preferred at set prices and a $3.5M convertible note. A 1-for-6.42441 reverse split occurred July 28, 2026, and preferred converted with Latigo’s Aug. 10 IPO.
How this was made
The 30-second read
Why it matters
The key new information is the disclosed capital-structure and ownership path: large preferred purchases at specified prices, a $3.5M convertible note issued in June 2026, and IPO-related conversion into common stock. This can affect perceived float, overhang, and sentiment around insider/holder conviction, but the excerpt does not provide a clear near-term catalyst like a tender offer or new financing terms.
Market read
Traders may reassess ALMS’s shareholder base and potential selling/holding intentions after the IPO conversion, but the excerpt lacks explicit intent changes or new deal terms.
What to watch
Reverse split and preferred-to-common conversion can distort apparent share counts; traders should focus on post-conversion beneficial ownership and any stated intent to sell, which is only partially shown in the excerpt.
Background
The excerpt is a Schedule 13D describing venture funds’ beneficial ownership in Latigo Biotherapeutics, including prior preferred purchases, a convertible note, a 1-for-6.42441 reverse split, and automatic conversion upon the August 10, 2026 IPO closing.
Ticker impact
Latigo Biotherapeutics files a Schedule 13D showing Foresite funds bought convertible preferred and common in its IPO, plus a $3.5M convertible note.
Near-term impact is likely limited unless the market interprets the holder’s stake as signaling confidence or future selling risk.
This is a new SEC filing with concrete transaction details (preferred purchases, convertible note, reverse split, IPO conversion), but it does not include new operating results, guidance, or a change in control.
Market effects
Adds incremental signal on financing and ownership dynamics in small-cap biotech, but no direct read-across to specific peers is provided.
No clear regional market linkage beyond US microcap biotech ownership/IPO activity.
No global macro or cross-border transaction details are disclosed.
Counterpoint
The holder’s activity may be largely mechanical (conversion after IPO and prior financing rounds) rather than a new bullish thesis, limiting tradable signal.
Key entities
- issuerLatigo Biotherapeutics, Inc.
Subject of the Schedule 13D, with common stock and prior convertible preferred and note converting upon its IPO.
- reporting personForesite Capital Fund VI LP
Venture fund filing as a reporting person, including purchases of convertible preferred and common in the IPO.
- reporting personForesite Capital Management VI, LLC
General partner entity with voting and disposition power over Fund VI shares.
- individualJames B. Tananbaum
Managing member of the general partners and a board member of the issuer.
